Discovering Potential Drug Targets and Biomarkers with HPC (G79885)

Target Name: HDAC11

NCBI ID: G79885

HDAC11

Discovering Potential Drug Targets and Biomarkers with HPC

High-performance computing (HPC) has revolutionized the field of biotechnology, enabling researchers to analyze large amounts of data at a faster pace. One of the most promising applications of HPC is in the discovery of drug targets and biomarkers. In this article, we will explore the HDAC11 gene, also known as HDA11_HUMAN, which is a promising drug target and biomarker for various diseases.

The HDAC11 gene is a member of the homolog (HMG) family, which is characterized by a specific domain called 11 (HDAC11). This gene is located on chromosome 17, and it encodes a protein known as HDAC11. The primary function of the HDAC11 protein is to regulate the activity of enzymes known as 3-hydroxy-3-methylacetyl-CoA reductase (HMG-CoA reductase), which is involved in the metabolism of various compounds, including drugs.

HDAC11 plays a crucial role in the regulation of cellular processes that are essential for human health, such as cell growth, apoptosis, and inflammation. It is also involved in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

One of the most significant aspects of the HDAC11 gene is its potential as a drug target. The HDAC11 protein has been shown to play a role in the inhibition of various drugs, including anti-cancer agents, which has led to its potential as a therapeutic agent for various diseases.

In addition to its potential as a drug target, HDAC11 has also been identified as a potential biomarker for several diseases. The HDAC11 gene has been shown to be downregulated in various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. This suggests that HDAC11 may be a useful biomarker for these diseases, as therapeutic approaches that target the HDAC11 gene may be effective in treating these conditions.

HPC is a powerful tool for the discovery of drug targets and biomarkers, and the study of HDAC11 is no exception. By using HPC to analyze the HDAC11 gene and its expression, researchers have been able to identify potential drug targets and biomarkers for various diseases.

In conclusion, the HDAC11 gene is a promising drug target and biomarker for various diseases. Its function in the regulation of cellular processes and its potential as a therapeutic agent make it an attractive target for researchers to investigate further. The use of HPC in the discovery of HDAC11-related compounds and therapies is an promising development in the field of biotechnology, and it holds promise for the treatment of a variety of diseases.

Protein Name: Histone Deacetylase 11

Functions: Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4). Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes

The "HDAC11 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HDAC11 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets